A clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, particularly Alzheimer’s disease. Its lead drug candidate, simufilam, has been the subject of clinical trials and regulatory scrutiny, drawing significant attention from both biotech investors and ...
This page tracks all publicly disclosed congressional trades in Cassava Sciences, Inc. (SAVA), a company in the Healthcare sector. 1 member of Congress has disclosed trades in this stock, including 3 purchases and 2 sales. All data is sourced from STOCK Act Periodic Transaction Reports filed with the House and Senate disclosure offices.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-12-12 | Christopher L. Jacobs | buy | $1K – $15K |
| 2022-11-08 | Christopher L. Jacobs | sell | $1K – $15K |
| 2022-10-12 | Christopher L. Jacobs | buy | $1K – $15K |
| 2022-07-18 | Christopher L. Jacobs | sell | $1K – $15K |
| 2022-06-21 | Christopher L. Jacobs | buy | $15K – $50K |